Diversity of malignancies in patients with different types of inborn errors of immunity.
Hematologic cancers
Inborn errors of immunity
Leukemia
Lymphoma
Malignancy
Primary immunodeficiency
Solid tumors
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
12 Dec 2022
12 Dec 2022
Historique:
received:
04
05
2022
accepted:
30
11
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
13
12
2022
Statut:
epublish
Résumé
Genetic defects in the development, maturation, and/or function of the immune cells can lead to Inborn errors of immunity (IEI) which may predispose patients to malignancies. The overall risk for cancer in children with IEI ranges from 4 to 25% and the type of malignancy is highly dependent on the specific mutant gene underlying IEI. We investigated 3056 IEI patients registered in the Iranian national registry between the years 1999 and 2020 in this retrospective cohort study. The frequency of malignancy and its association with the type of IEI in these patients were evaluated. A total of 82 IEI patients with malignancy were enrolled in this study. Among them, predominantly lymphoma was the most common type of malignancy (67.1%), followed by leukemia (11%), and cancers of the head and neck (7.3%). Among identified lymphoma cancers, non-Hodgkin's lymphomas were the most frequent type (43.9%) followed by different subtypes of Hodgkin's lymphoma (23.2%). Solid tumors (18.3%) appeared to be very heterogeneous by type and localization. The correlation between the type of malignancy and survival status and the association between the type of malignancy and IEI entities were unremarkable. The awareness of the association between the presence of IEI and cancer highlights the importance of a synergistic effort by oncologists and immunologists in the early diagnosis of malignancy and personalized therapeutic strategies in IEI patients.
Identifiants
pubmed: 36510326
doi: 10.1186/s13223-022-00747-2
pii: 10.1186/s13223-022-00747-2
pmc: PMC9743521
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106Subventions
Organisme : Alborz University of Medical Sciences
ID : IR.ABZUMS.REC.1398.232
Informations de copyright
© 2022. The Author(s).
Références
Front Immunol. 2021 Aug 17;12:720025
pubmed: 34484227
Am J Hematol. 2011 Jan;86(1):48-55
pubmed: 21120868
Annu Rev Med. 1988;39:63-73
pubmed: 3285791
J Allergy Clin Immunol. 2018 Mar;141(3):1028-1035
pubmed: 28606585
Curr Pediatr Rev. 2019;15(4):245-250
pubmed: 31530267
J Clin Immunol. 2018 Jan;38(1):96-128
pubmed: 29226302
Blood. 2010 Aug 26;116(8):1228-34
pubmed: 20466855
J Clin Immunol. 2018 Oct;38(7):816-832
pubmed: 30302726
Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):61
pubmed: 30275850
Front Immunol. 2019 Feb 12;9:3136
pubmed: 30809233
Blood. 2010 Aug 26;116(8):1189-90
pubmed: 20798238
Biology (Basel). 2021 Apr 09;10(4):
pubmed: 33918597
J Allergy Clin Immunol. 2018 Jan;141(1):59-68.e4
pubmed: 28669558
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393912
Immunol Allergy Clin North Am. 2015 Nov;35(4):599-623
pubmed: 26454309
Front Pediatr. 2019 Jun 19;7:232
pubmed: 31275905
J Clin Immunol. 2020 Jan;40(1):66-81
pubmed: 32048120
Front Immunol. 2018 Dec 12;9:2912
pubmed: 30619276
Immunodeficiency. 1994;5(2):91-112
pubmed: 8032367
J Clin Immunol. 2021 Aug;41(6):1339-1351
pubmed: 34052995